



The Commonwealth of Massachusetts
Executive Office of Health and Human Services
Department of Public Health
William A. Hinton State Laboratory Institute
305 South Street, Jamaica Plain, MA 02130

DEVAL L. PATRICK
GOVERNOR

JOHN W. POLANOWICZ
SECRETARY

CHERYL BARTLETT, RN
COMMISSIONER

Bureau of Infectious Disease
Division of Epidemiology and Immunization
Tel: (617) 983-6800
Fax: (617) 983-6840
www.mass.gov/dph/epi
www.mass.gov/dph/imm

To: Pediatric Vaccine Providers

From: Pejman Talebian, MA, MPH, Director, Immunization Program
Susan M. Lett, MD, MPH, Medical Director, Immunization Program

Date: July 22, 2013

Subject: Two New Vaccines Added to MDPH Formulary:
1) Combination Vaccine: Kinrix (DTaP-IPV)
2) Choice of Tdap formulation: Boostrix (in addition to Adacel)

The Massachusetts Department of Public Health (MDPH) is pleased to announce the availability of two additional vaccines to its current formulary effective August 1, 2013. This expansion in the MDPH vaccine formulary is as a result of a formal recommendation to the Department by the Massachusetts Vaccine Purchasing Advisory Council (MVPAC) after deliberations during their April 2013 meeting. These vaccines will allow vaccine providers more options for diphtheria, tetanus, and pertussis containing vaccines.

Vaccines Available

1) Kinrix (DTaP-IPV), manufactured by GlaxoSmithKline (GSK), is a combination vaccine approved for the 5th dose of DTaP and 4th dose of IPV vaccines in children 4 through 6 years whose previous DTaP doses have been with GSK's Pediarix (DTaP-HepB-IPV) and/or GSK's Infanrix (DTaP).

Although the Advisory Committee on Immunization Practices (ACIP) recommends that the DTaP series be completed with the same brand if possible, limited data suggest that "mix and match" of the DTaP series does not adversely affect safety and immunogenicity. As such, ACIP recommends providers complete the DTaP series with whichever formulation is available to avoid missed opportunities. Providers wishing to decrease the number of injections may choose to use Kinrix in children who received other vaccines for their earlier doses in the series. Please refer to the table on the next page for summary guidance from the ACIP about Kinrix, including its permissive use.

2) Boostrix, manufactured by GSK, is the second Tdap vaccine being added to the current MDPH vaccine formulary. Over the past several years, MDPH has been supplying Adacel, manufactured by Sanofi Pasteur (SP), for all Tdap orders. The addition of Boostrix offers providers another option for Tdap vaccine.

Please see the table below for summary guidance from ACIP about Tdap, including its permissive use in certain age and risk groups.

Kinrix and Tdap Vaccine Guidance¹

Vaccine	Manufacturer	Recommended Use Summary
DTaP Vaccines for Children Younger Than 7 Years of Age		
DTaP-IPV (Kinrix)	GSK	Booster dose for 5th dose of DTaP and 4th dose of IPV at 4 through 6 years in children whose previous DTaP doses have been with GSK's Pediarix (DTaP-HepB-IPV) and/or GSK's Infanrix (DTaP) ¹
Tdap Vaccines for Adolescents and Adults		
Tdap (Boostrix)²	GSK	<ul style="list-style-type: none"> • 1 dose for nonpregnant individuals ≥ 7 years: <ul style="list-style-type: none"> ○ Children 7-10 years not fully vaccinated with DTaP⁴ ○ Adolescents 11-18 years, (preferably at 11-12 years) ○ Adults ≥ 19 years⁵ • 1 dose with every pregnancy (ideally at 27-36 weeks gestation)⁶
Tdap (Adacel)³	SP	

¹ The ACIP recommends that the DTaP series be completed with the same brand of vaccine -- if possible. Limited data suggest that "mix and match" of the DTaP series does not adversely affect the safety and immunogenicity. They recommend providers complete the series with whichever formulation is available, including Kinrix, to avoid missed opportunities. ([CDC. Pink Book, 12th Ed. Pertussis Chapter: pages:222-226.](#))

² Boostrix is approved for those ≥ 10 years.

³ Adacel is approved for those 11-64 years.

⁴ ACIP recommends both Boostrix and Adacel be used for those 7-10 years who are not fully vaccinated with DTaP (defined as 5 doses of DTaP or 4 doses of DTaP if the 4th dose was administered on or after the 4th birthday). ([CDC. MMWR 2011;60:13-15.](#))

⁵ Whenever feasible, Boostrix should be used for those ≥ 65 years. However, according to ACIP, Adacel is a valid option for this age group if Boostrix is not available. ([CDC. MMWR 2012;61:468-470.](#))

⁶ The ACIP recommends a dose of Tdap with every pregnancy, regardless of the number of years since last dose of Td or Tdap vaccination ([CDC. MMWR 2013;62:131-135.](#))

Vaccine Ordering

Please be sure to use the latest version of the MDPH *Vaccine Order Form* and *Vaccine Aggregate Report Form* attached and also available on the MDPH website at www.mass.gov/dph/imm.

If you decide to choose a new formulation, please use up existing inventories prior to making the change. Please be sure that you never let vaccine doses expire before use or restitution (in the form of privately purchasing replacement doses) may be required. The Immunization Program will monitor vaccine orders to ensure that practices are routinely ordering the same vaccine brand and only infrequently making brand changes.

Questions

For questions about **vaccine availability and ordering**, please call the Vaccine Management Unit at 617-983-6828.

For questions about **vaccine recommendations** for DTaP-IPV and Tdap vaccines, please call the Immunization Program at 617-983-6800 and ask to speak to an immunization epidemiologist or nurse.